LY3962681 / Eli Lilly - LARVOL DELTA

PROSPECT: A FIRST-IN-HUMAN SINGLE AND MULTIPLE ASCENDING DOSE TRIAL OF A NOVEL INTRATHECALLY DELIVERED SIRNA TARGETING Α-SYNUCLEIN MRNA FOR THE TREATMENT OF PARKINSON'S DISEASE (ADPD 2025) - P1 | "LY3962681 is a first-in-class, investigational small interfering RNA (siRNA) agent administered intrathecally, targeting α-synuclein (SNCA) mRNA to reduce ASYN production...The study will assess safety and inform dosing and dosing intervals. Further study design details and regulatory updates will be presented."

P1 data • CNS Disorders • Movement Disorders • Parkinson's Disease • SNCA

First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson's Disease (MDS Congress 2024) - "m"

Clinical • P1 data • CNS Disorders • Parkinson's Disease • SNCA

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: Prevail Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study in Healthy Volunteers and a Double-blind, Placebo-controlled, Multiple-ascending-dose Study in Patients With Parkinson's Disease to Evaluate the Safety, Tolerability, and PK/PD of LY3962681 (clinicaltrials.gov) - P1 | N=108 | Not yet recruiting | Sponsor: Prevail Therapeutics

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease